Bretisilocin | MedDataX

Drug Profile

Bretisilocin is an investigational next-generation short-acting serotonergic psychedelic compound in clinical development for major depressive disorder. AbbVie completed acquisition of this lead candidate from Gilgamesh Pharmaceuticals in October 2025 to expand its psychiatry pipeline. The program is currently in Phase 2 development.

Drug Class: Short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser
Approval Status: Investigational; currently in Phase 2 clinical development
Mechanism of Action: Acts as a serotonin 5-HT2A receptor agonist and serotonin releaser

Brand Names

bretisilocin

Indications

\Moderate-to-severe major depressive disorder (MDD)\

Related News

Enveric Biosciences Reports Positive Preclinical Results for EB-003 and Corporate Updates

Mar 28, 2026

Enveric Biosciences reports positive preclinical results for lead candidate EB-003 showing efficacy in depression and PTSD models. The company has completed pre-IND studies and received FDA feedback for streamlined IND submission, with plans for Phase 1 trials in 2026. New BRET assay data demonstrates EB-003's engagement of therapeutic signaling pathways while independent research supports separation from hallucinogenic effects.

AbbVie Projects Strong 2026 Growth as Skyrizi and Rinvoq Replace Humira

Feb 13, 2026

AbbVie projects 43-45% earnings growth in 2026 as newer immunology drugs Skyrizi and Rinvoq offset declining Humira sales, while maintaining its 54-year dividend increase streak as a Dividend King.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07604558	A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants	NOT_YET_RECRUITING	PHASE1